NEW YORK – Oncocyte on Friday priced a public offering of 7,780,000 shares of its common stock at $4.50 per share.
The Irvine, California-based firm expects gross proceeds from the offering to be about $35 million. It also is granting underwriters a 30-day option to purchase up to an additional 1,167,000 shares of its common stock at the same price.
Piper Sandler is acting as the sole book-runner for the offering, which is expected to close on or about Feb. 9. BTIG and Needham are acting as co-lead managers.